cash receipts are actually up 100k from last quarter.
less interest from deposits as increased costs from R&D and Sales and marketing.
Like i posted, this is a settling quarter. The Rome symposium would have cost a bomb and there will be no sales reflected from that in this report. However, next quarter should see sales flow through.
As the company stated:
March Quarter revenues are historically the lowest of the year due to reduced demand for respiratory products during the Australian summer and relatively feweraesthetic and other elective procedures during January in Europe.
All in all, a very good report showing strong consistant growth with ReCell.
quarterly out, page-4
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.50 |
Change
-0.150(4.11%) |
Mkt cap ! $244.5M | |||
| Open | High | Low | Value | Volume |
| $3.79 | $3.85 | $3.32 | $3.375M | 944.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $3.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.53 | 19524 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |